| 英文别名 |
9,11-Didehydroestriol;Estra-1,3,5,9(11)-tetraene-3,16a,17b-triol;(8S,13S,14S,16R,17R)-13-methyl-6,7,8,12,14,15,16,17-octahydrocyclopenta[a]phenanthrene-3,16,17-triol;9,11-Didehydrooestriol;A,17;A-triol;Estra-1,3,5,9(11)-tetraene-3,16;Estra-1,3,5,9(11)-tetraene-3,16alpha,17beta-triol;Estra-1,3,5(10),9(11)-tetraene-3,16alpha,17beta-triol; Estriol Imp. A (EP); 9,11-Didehydroestriol; Estriol Related Compound A; Estriol Impurity A;Estra-1,3,5(10),9(11)-tetraene-3,16,17-triol, (16alpha,17beta)-;J-015586;(1R,2R,3aS,3bS,11aS)-11a-methyl-1H,2H,3H,3aH,3bH,4H,5H,11H,11aH-cyclopenta[a]phenanthrene-1,2,7-triol;9(11)-Didehydroestriol;Estra-1,3,5(10),9(11)-tetraene-3,16alpha,17beta-triol;(8S, 13S, 14S, 16R, 17R)-13-methyl-6, 7, 8, 12, 14, 15, 16, 17-octahydrocyclopenta[a]phenanthrene-3, 16, 17-triol;ESTRA-1,3,5(10),9(11)-TETRAENE-3,16,17-TRIOL, (16.ALPHA.,17.BETA.)-;Estriol impurity A, European Pharmacopoeia (EP) Reference Standard;UNII-2FEM8A2HAS;Estra-1,3,5(10),9(11)-tetraene-3,16,17-triol;2FEM8A2HAS;DTXSID50432933;ZWHFPHWLYUMTGY-WKULXVSPSA-N;246021-20-5;Estra-1,3,5(10),9(11)-tetraene-3,16alpha,17beta-triol (9,11-Didehydroestriol) |
